** Shares of gene therapy maker Sarepta Therapeutics SRPT.O fall 21.3% to $36.80 in aftermarket trade
** Company sees 2025 net product revenue of $2.3 billion to $2.6 billion, compared to previous expectation of $2.9 billion to $3.1 billion
** Company reports adjusted Q1 loss of $3.42/shr, vs analysts' average loss estimate of 95 cents/shr, according to data compiled by LSEG
** SRPT shares, along with those of other gene therapy developers, had plummeted earlier in the day after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research
** Up to last close, stock down 61.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。